AHR and pancreatic ductal adenocarcinoma: The depletion of AHR in myeloid cells or the inhibition of AHR by antagonistic treatment reduces the progression of pancreatic ductal adenocarcinoma (PDAC) by diminishing the immunosuppressive function of TAMs and enhancing immune surveillance by CD8+ T cells.